| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c3b89f8a9549bfb17b87cc8c157c7532
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_99846dc1aa30cac78658754457d392ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c0d2ae31c3e078e4db0b58abd07ac590
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_df6a47e123313c42cc4af35c4862daf6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e232689f4a1fc9ec99d4344c059b061b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5154 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001194
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N37-18 |
| filingDate |
2006-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2012-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b548cad46ccd8f4f85141b907078a11a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84ea7930de5045aefef109cb8a6c7549
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a288559951aa92248ddb750c4e74770
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c40568c7d69e4d86f672740ec0163966 |
| publicationDate |
2012-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8293701-B2 |
| titleOfInvention |
Methods and compositions relating to a vaccine against prostate cancer |
| abstract |
An object of the invention is to provide methods and compositions relating to a vaccine against prostate cancer which includes a non-human-primate PSA for administration to humans to provide an immune response against human PSA. More generally, an object of the invention is to provide methods and compositions relating to using a non-human primate xenogeneic antigen (e.g. protein) in a human, wherein, with respect to the non-human primate xenogeneic antigen that is used, there are relatively few interspecies differences between the non-human primate xenogeneic antigen and the human self antigen in order to induce an optimal immune response in the human to its native self antigen. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017143062-A1 |
| priorityDate |
2005-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |